GYRUS Technology
Our lead candidate, GY-015, is a patent-protected peptide with novel mechanism of action targeting multiple aspects of the Alzheimer's disease cascade, thereby reversing Alzheimer's progression.
We are developing our lead candidate as an intranasal delivered drug, employing a proprietary nanoparticle delivery system.
Our proprietary approach to Alzheimer's treatment is anticipated to address the challenges faced by Alzheimer's drugs that have failed in development.
